Novo Nordisk Cuts US Sales Team: Cost-Cutting?
Update: 2025-09-18
Description
Novo Nordisk slashes its U.S. obesity and diabetes education team in a major restructuring, signaling a cost-cutting strategy to rival Eli Lilly and recover from a $400 billion market cap loss. Find out how this move, impacting hundreds of employees, reflects a shift in Novo's approach to the competitive weight loss drug market.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
